Global Markets for Enzyme Inhibitors

Published - Jun 2012| Code - BIO057B| Publisher - BCC Publishing

Report Highlights

The global market for enzyme inhibitors was valued at $104.4 billion in 2010 and reached nearly $104.6 billion in 2011. This market is expected to rise at a compound annual growth rate (CAGR) of 4% and reach nearly $127.4 billion by 2016.

Report Scope

The scope of this study encompasses enzyme inhibitors in the pharmaceutical and biotechnology industry.  BCC Research analyzes each market and its applications, regulatory environment, technology involved, market projections and market share.  Technological issues include the latest trends and developments.  Emerging markets for enzyme inhibitors include countries such as India, China, Japan, Korea, Taiwan, Canada, Africa, Australia and New Zealand.

Analyst Credentials

Shalini Shahani Dewan focuses on pharmaceuticals and biotechnology and has been a BCC Research contributor since 2002 as both an analyst and project manager. She has explored a wide range of topics and companies, including working for Johnson & Johnson doing market surveillance. She has an undergraduate degree in pharmacy and master's degree in medicinal chemistry. She resides in the Bay Area.

Latest reports include:

Table of Contents & Pricing

All reports provided in PDF format. For shared licensing options (5+ Users), please call a representative at (+1) 781-489-7301 or contact us at info@bccresearch.com
Title/Chapter Name Pages Price Member Price
Full Report: Global Markets for Enzyme Inhibitors 315 $2,750 Free
Chapter- 1: INTRODUCTION4Free
Chapter- 2: SUMMARY3$250Free
Chapter- 3: OVERVIEW22$192Free
Chapter- 4: REGULATORY ASPECTS8$70Free
Chapter- 5: MARKET LEADERS AND THEIR PRODUCTS FOR ENZYME INHIBITORS6$52Free
Chapter- 6: NEW DEVELOPMENTS15$131Free
Chapter- 7: GLOBAL MARKETS60$524Free
Chapter- 8: MARKETS IN THE UNITED STATES54$471Free
Chapter- 9: MARKETS IN EUROPE52$454Free
Chapter- 10: EMERGING MARKETS49$428Free
Chapter- 11: PATENT ANALYSIS10$87Free
Chapter- 12: CURRENT SITUATION 6$52Free
Chapter- 13: COMPANY PROFILES24$210Free
Chapter- 14: APPENDIX—ABBREVIATIONS2$17Free
Published - Jun-2006| Analyst - Lynn Gray| Code - BIO057A

Report Highlights

  • During the forecast period, enzyme-inhibiting drugs are projected to be introduced for new indications including asthma and chronic obstructive pulmonary disease (COPD), pulmonary arterial hypertension, hepatitis C and intermittent claudication.
  • Recent withdrawals of products in the COX-2 inhibitor class along with recent and future introductions of novel products in other classes will rearrange the market share of categories in the enzyme inhibitor sector. Overall, the market for products included in this report is expected to show an average annual growth rate (AAGR) of approximately 6.7% from 2005 to 2011, increasing from $29.2 billion to $43.1 billion.
  • Of all the inhibitor categories, COX-2 and PDE4 will see increases in revenue share for the period 2005 to 2011. Cox-2 inhibitors' share will grow from 12.7% to 18.9%, while PDE4 inhibitors will increase from zero in 2005 to 3.6% in 2011.

RELATED REPORTS
Share This Report